| This week's sponsor is CMIC Group. | | | Partner with Japan’s Largest CRO for your global drug development
CMIC is the largest CRO in Japan, with extended services in drug development and GMP manufacturing, site management, regulatory consulting and contract sales. We have the full end to end solution to help you enter Japan market and fulfill your drug development and manufacturing needs in US, Japan and Asia. To learn more, click here. |
Today's Rundown Pfizer and Lilly claim win for NGF pain drug in osteoarthritis Sanofi bags rights to Revolution’s SHP2 cancer drug U.K. votes to ‘fully participate’ in EMA after Brexit Ovid, Takeda add 2 rare epilepsies to rare drug pact Bill Gates and others launch $30M ‘venture philanthropy’ accelerator for Alzheimer’s diagnostics Under scrutiny for Cohen deal, Novartis calls off further price hikes in 2018 Featured Story | | | Wednesday, July 18, 2018 Pfizer and Eli Lilly’s nerve growth factor (NGF) inhibitor tanezumab has inched closer to becoming the first alternative to opioid analgesics for severe pain after hitting the mark in a phase 3 trial. |
|
|
Top Stories Wednesday, July 18, 2018 Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drugs against SHP2. The partners plan to move small molecule SHP2 inhibitor RMC-4630 into the clinic later this year. Wednesday, July 18, 2018 British politicians have voted for the U.K. to try to remain close to the EMA after Brexit. The voted-for text tasks the government with seeking to secure the right for the U.K. to “fully participate” in the regional regulatory network after it leaves the European Union. Wednesday, July 18, 2018 The pair will start three new trials in the third quarter, including a phase 2 pilot study in CDKL5 deficiency disorder and duplication 15q syndrome. Wednesday, July 18, 2018 High-profile investors led by billionaires Bill Gates and Leonard Lauder are throwing their weight behind a “venture philanthropy vehicle” offering more than $30 million in grants for new biomarkers and early diagnostic tests for Alzheimer’s disease. Wednesday, July 18, 2018 Even before Pfizer faced the wrath of U.S. President Donald Trump for July price hikes, Novartis decided increasing its own prices wouldn’t be a prudent move, its CEO said Wednesday. | This week's sponsor is ExL Events. | | | |
Resources Sponsored by: Veeva See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Sponsored by: Patheon, part of Thermo Fisher Scientific Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies. What should pharma companies look for when navigating this new era of small-volume manufacturing? Here are some ideas to consider when developing a new manufacturing strategy. Drug Approval, Manufacturing Quality & Regulation 2018 | Online The Life Science Women's Conference August 8-9, 2018 | Austin, Texas Join 200+ Service and Support Leaders at Field Service Amelia Island this August August 27-29, 2018 | Amelia Island, FL RESI HealthTech Week September 5-7, 2018 | Boston, MA 2018 Latin America Healthcare Compliance Certification Program Sao Paulo, Brazil | Sep 24-27, 2018 Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA 10th International Leaders in Biobanking Congress October 14-16, 2018 | Cleveland, OH BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation |
